News|Articles|May 28, 2025
Do New Antiobesity Meds Still Require Lifestyle Management?
Listen
0:00 / 0:00
Key Takeaways
- Pharmacotherapy targets appetite signaling, yet lifestyle modification addresses environmental and behavioral drivers that medications cannot fully correct, particularly for cardiometabolic comorbidity control.
- Intensive behavioral therapy provides structured goal setting, self‑monitoring, and problem solving that improves adherence to GLP‑1/GIP agents and sustains weight loss trajectories.
Are lifestyle interventions still necessary when medications like semaglutide and tirzepatide are so effective?
Learn How To Introduce a Turnkey Evidence Based Nutrition Counseling Program to Your Practice.
Discover evidence-based guidance on how and why lifestyle counseling remains a cornerstone of obesity care—even in the era of highly effective, hormone-based pharmacotherapy.
Inside you'll learn:
- Why lifestyle management remains foundational—even with GLP-1 and GIP-based medications
- The clinical value of intensive behavioral therapy (IBT) alongside pharmacologic treatment
- Key findings from STEP, SURMOUNT, and Look AHEAD trials
Adding a lifestyle management nutrition counseling program to your practice has both clinical and economic benefits.
Sponsored by:
Related Content
Trending on Medical Economics
1
How to fix health care: Start with primary care, AHA says
2
Doctor's orders aren't enough: Insurance denials leave millions delayed, sicker and in debt
3
Federal immigration policy could deepen physician shortages where they’re already worst, study finds
4
From system of record to system of work: The technology keeping practices independent
5